VILDAPRL D10 TAB

Distributor inventory | Tablet

Type 2 diabetes mellitus (as add-on to diet and exercise) to improve glycaemic control when dual therapy is appropriate.

Vildagliptin is a DPP-4 inhibitor that increases incretin hormones, leading to increased insulin release and reduced glucagon in a glucose-dependent manner. Dapagliflozin is an SGLT2 inhibitor that lowers blood glucose by increasing urinary glucose excretion via the kidneys.

Take orally exactly as prescribed by a doctor. Usually taken once daily, with or without food, at the same time each day; swallow whole with water. Monitor blood sugar regularly; maintain diet and exercise.

Genital fungal infection,urinary tract infection,increased urination,thirst,dehydration,dizziness,headache,nausea,diarrhoea,nasopharyngitis,hypoglycaemia (especially with insulin/sulfonylureas)

Prescription-only antidiabetic. Risk of dehydration/low blood pressure—ensure adequate fluids, especially in elderly or on diuretics. SGLT2 inhibitors may rarely cause diabetic ketoacidosis (can occur with near-normal sugars); seek urgent care for nausea, vomiting, abdominal pain, fast breathing, confusion. Increased risk of genital mycotic infections and UTIs; maintain hygiene and seek care if symptoms occur. Monitor kidney function; not recommended in severe renal impairment/end-stage kidney disease. Use caution in hepatic impairment; vildagliptin can rarely affect liver enzymes—periodic LFTs may be advised. Risk of pancreatitis with DPP-4 inhibitors—stop and consult if severe persistent abdominal pain. Not for type 1 diabetes.